Identification of two distinct mesenchymal stromal cell populations in human malignant glioma.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27757723)

Published in J Neurooncol on October 18, 2016

Authors

Andreas Svensson1,2, Tania Ramos-Moreno3,4, Sofia Eberstål1,2, Stefan Scheding1,5, Johan Bengzon1,2

Author Affiliations

1: Lund Stem Cell Center, BMC B10, Lund University, Klinikgatan 26, 221 84, Lund, Sweden.
2: Department of Clinical Sciences, Division of Neurosurgery, Lund University, Box 117, 221 00, Lund, Sweden.
3: Lund Stem Cell Center, BMC B10, Lund University, Klinikgatan 26, 221 84, Lund, Sweden. tania.ramos_moreno@med.lu.se.
4: Department of Clinical Sciences, Division of Neurosurgery, Lund University, Box 117, 221 00, Lund, Sweden. tania.ramos_moreno@med.lu.se.
5: Department of Hematology, Skåne University Hospital, Lund, Sweden.

Articles cited by this

The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66

Mesenchymal stem cells. J Orthop Res (1991) 10.98

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood (2003) 4.43

Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther (2004) 2.97

Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50

MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood (2009) 2.33

Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther (2010) 2.29

Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res (2007) 1.97

PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med (2013) 1.95

Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther (2008) 1.61

Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells (2006) 1.56

Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol (2007) 1.42

Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia (1996) 1.35

VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun (2008) 1.26

Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res (2010) 1.24

Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy (2008) 1.17

Mesenchymal stem cell signaling in cancer progression. Cancer Treat Rev (2012) 1.10

Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. Stem Cells Int (2012) 1.09

Getting a grip on Thy-1 signaling. Biochim Biophys Acta (2008) 1.07

Stem cell-based therapy for malignant glioma. Cancer Treat Rev (2012) 1.07

To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget (2013) 1.05

Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev (2009) 1.04

Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncol Rep (2010) 1.02

Decreased CD90 expression in human mesenchymal stem cells by applying mechanical stimulation. Head Face Med (2006) 0.99

Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells (2015) 0.99

The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med (2015) 0.97

THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet Cytogenet (2003) 0.97

Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol (2013) 0.89

Primary mesenchymal stem cells in human transplanted lungs are CD90/CD105 perivascularly located tissue-resident cells. BMJ Open Respir Res (2014) 0.84

Peripheral CD4+ T cell maturation recognized by increased expression of Thy-1/CD90 bearing the 6C10 carbohydrate epitope. J Immunol (1999) 0.83

Rat multipotent mesenchymal stromal cells lack long-distance tropism to 3 different rat glioma models. Neurosurgery (2012) 0.81